Will patients in a myeloma clinical trial in China receive an inactive placebo?

No. In life-threatening hematologic malignancies, institutional ethics review boards in China strictly forbid pure-placebo control arms. Randomized registrational Phase 3 trials always provide the national standard of care (such as established triplets or quadruplets) to the control group, ensuring baseline efficacy and patient safety are never compromised.

Can a participant withdraw from a Chinese clinical trial after signing informed consent?

Yes, at any time without penalty. Under NMPA GCP guidelines, informed consent is a voluntary agreement, not a binding contract. Participants retain the unconditional legal right to leave a trial at any stage for any personal reason, and treating physicians are prohibited from altering standard clinical care as a result.

What medical expenses are covered by the trial sponsor in China?

Sponsors fully cover investigational drugs or cell products, protocol-mandated laboratory monitoring, bone marrow aspirates, and scheduled PET-CT/MRI scans. General ward bed fees and concurrent medications for pre-existing conditions (such as diabetes or hypertension) remain billed through standard insurance. Most trials also provide travel stipends.

How can families verify whether a Chinese clinical trial is legitimate?

Look for three official hallmarks: 1. A verifiable registration code on the NMPA CDE platform (prefixed with CTR); 2. A formal approval letter from the tertiary hospital's Institutional Review Board (IRB); 3. Absolute absence of registration or matching fees. Any third party demanding broker fees to access a trial is illegitimate.

How long does it take from medical prescreening to receiving the first trial dose?

The standard sequence spans five phases: medical record prescreening, signing the Informed Consent Form (ICF), comprehensive baseline screening (1 to 2 weeks), drug washout (typically 2 to 4 weeks), and official enrollment. The entire process generally requires 2 to 4 weeks.

Back to Guidelines

newly-diagnosedactive-treatmentrelapse-refractory

How Patients Navigate and Enroll in Clinical Trials Across China

Name: How Patients Navigate and Enroll in Clinical Trials Across China | CMDN
Creator: CMDN Editorial Team

Patient Roadmap · Official Registry Portals, Informed Consent Rights, and Protections

Medical Disclaimer: The following content is compiled based on the latest authoritative guidelines at home and abroad. It is for reference only for patients and their families and cannot replace the professional medical advice of the attending physician. Please be sure to follow the doctor's advice for the treatment plan.

How can patients explore clinical trials in China?

Evaluating an interventional clinical trial in China is an established medical pathway, protected by national regulatory statutes and independent ethics committees: joining a trial is not a desperate gamble, but an early, zero-cost access channel to breakthrough therapies.

Families navigating China's oncology landscape should understand the structural protections, verified registry portals, and legal rights that govern all authorized studies.

1. Verifying Trial Authenticity in China

Every authorized interventional trial in mainland China must be formally registered and approved before subject recruitment begins. Legitimate trials can be validated through three checks:

National Medical Products Administration (CDE) Registry Code: All commercial and registrational studies carry a public registration number beginning with CTR (e.g., CTR20241656), searchable on the official CDE portal (chinadrugtrials.org.cn).
Institutional Review Board (IRB) Approval: The protocol must hold a written approval seal from the host hospital's independent medical ethics committee, explicitly detailing patient protections and safety stopping rules.
Strict Zero-Fee Policy: Clinical trial enrollment in China is 100% free of charge. Under national GCP law, neither hospitals, sponsors, nor investigators may charge patients an entrance fee, consulting fee, or broker commission. Commercial intermediaries charging "matching fees" are operating outside regulatory frameworks.

2. The Five-Step Standard Enrollment Roadmap

Navigating from initial inquiry to investigational administration follows five disciplined milestones:

Step 1: Record Collation ──> Step 2: Protocol Prescreen ──> Step 3: Informed Consent (ICF) ──> Step 4: Baseline Screening & Washout ──> Step 5: Day 1 Dosing

Step 1: Collate Primary Records: Gather initial bone marrow biopsy reports, cytogenetics (FISH), exact start/stop dates of each prior therapy line, and recent laboratory panels.
Step 2: Expert Prescreening: The Principal Investigator (PI) or study team assesses inclusion and exclusion criteria to confirm eligibility.
Step 3: Informed Consent (ICF): The doctor reviews the study rationale, potential toxicities, and alternative therapies in detail. The patient and caregiver sign voluntarily.
Step 4: Formal Screening & Washout: Free in-hospital testing verifies bone marrow and organ function, while a mandatory 2 to 4-week washout clears prior antimyeloma agents.
Step 5: Official Allocation and Dosing: Once all baseline parameters clear medical monitor review, treatment begins according to protocol schedule.

3. Financial Boundaries: Sponsor Coverage vs Self-Pay

The financial division in Chinese clinical research is transparent:

Covered by Trial Sponsor (Free)	Covered by Patient / Health Insurance
Investigational drugs, antibodies, and cellular products	Medications for unrelated pre-existing conditions (e.g., insulin, antihypertensives)
Protocol-mandated blood tests, flow cytometry, and MRD tests	Non-protocol diagnostic consultations
Protocol bone marrow biopsies and PET-CT / MRI scans	Routine transport and meals (often offset by scheduled trial stipends)
Treatment of protocol-related adverse events	Standard general ward bed co-pays if not sponsored

This guide is published by China Myeloma Digital Network (CMDN) to promote objective patient literacy and ethical trial navigation.

Your myeloma care companion

CMDN Care · Myeloma Companion

Organize your lab reports, follow biomarker trends, and prepare questions for your care team with CMDN’s English-language companion for myeloma patients and caregivers.

Open CMDN Care How CMDN Care works

Lab report OCR

Review results extracted from your reports.

Biomarker trends

Keep follow-up results in one place.

Visit preparation

Bring your questions to your care team.

Your share could light up hope for another patient 💛

FAQs

Will patients in a myeloma clinical trial in China receive an inactive placebo?: No. In life-threatening hematologic malignancies, institutional ethics review boards in China strictly forbid pure-placebo control arms. Randomized registrational Phase 3 trials always provide the national standard of care (such as established triplets or quadruplets) to the control group, ensuring baseline efficacy and patient safety are never compromised.
Can a participant withdraw from a Chinese clinical trial after signing informed consent?: Yes, at any time without penalty. Under NMPA GCP guidelines, informed consent is a voluntary agreement, not a binding contract. Participants retain the unconditional legal right to leave a trial at any stage for any personal reason, and treating physicians are prohibited from altering standard clinical care as a result.
What medical expenses are covered by the trial sponsor in China?: Sponsors fully cover investigational drugs or cell products, protocol-mandated laboratory monitoring, bone marrow aspirates, and scheduled PET-CT/MRI scans. General ward bed fees and concurrent medications for pre-existing conditions (such as diabetes or hypertension) remain billed through standard insurance. Most trials also provide travel stipends.
How can families verify whether a Chinese clinical trial is legitimate?: Look for three official hallmarks: 1. A verifiable registration code on the NMPA CDE platform (prefixed with CTR); 2. A formal approval letter from the tertiary hospital's Institutional Review Board (IRB); 3. Absolute absence of registration or matching fees. Any third party demanding broker fees to access a trial is illegitimate.
How long does it take from medical prescreening to receiving the first trial dose?: The standard sequence spans five phases: medical record prescreening, signing the Informed Consent Form (ICF), comprehensive baseline screening (1 to 2 weeks), drug washout (typically 2 to 4 weeks), and official enrollment. The entire process generally requires 2 to 4 weeks.

References used for this guide

Sincere thanks to the following authoritative institutions
for their academic support:

Lighting the hope of survival
for myeloma patients globally

Disclaimer: All disease knowledge, guideline interpretations, and treatment processes provided on this site are for learning and reference only, and do not constitute any medical advice or professional diagnosis. The condition of each patient is unique. For specific treatment plans and medication decisions, please be sure to follow the guidance of your attending physician or professional medical team.

This article is reviewed and published by the CMDN Editorial Team

Last updated: 2026-10-03

Get Support